Clinical Trial Update: Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal [Phase 4]

View source ↗

Summary

A completed Phase 4 trial evaluating the efficacy and tolerability of a 4-week course of tedizolid in prosthetic joint infections treated with implant removal.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prosthetic Joint Infection

Drugs mentioned

• Sivextro (tedizolid)

Snippet

Sponsor: Fundacion Clinic per a la Recerca Biomédica | Conditions: Prostheses Infection | Phase 4 | Status: COMPLETED